Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antrocin is a **naturally occurring sesquiterpene lactone** isolated primarily from the medicinal mushroom *Antrodia cinnamomea*. It has demonstrated **antiproliferative effects against multiple cancer cell types** (including breast, lung, prostate, and bladder cancers), exerting its effects by inhibition of tumor-promoting signaling pathways such as **PI3K/AKT, MAPK, JAK2/STAT3, IGF-1R, β-catenin, Notch1, and Akt**[1][2][3][8][10]. Preclinical studies show it can sensitize cancer cells to radiotherapy and potentiate the effect of chemotherapeutics like paclitaxel[2][3]. Antrocin also exhibits strong anti-oxidant and antimutagenic activities[1]. It has been evaluated for genotoxicity and oral toxicity in animal studies, showing a lack of significant toxicity at therapeutic reference doses[1]. Synthetic routes for antrocin as well as its isolation from fungal sources have been described[1][6][10][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antrocin.